Skip to main content
v2026.11,986 entries · CC-BY 4.0

NEJM Evidence: Journal Scope, Clinical Trial Standards, and Submission Guide

A comprehensive guide to NEJM Evidence, covering clinical trial methodology, manuscript submission in ScholarOne, article formats, and citation metrics.

Written and maintained by CASRAI Editorial Board

Published

On this page

NEJM Evidence is a digital-first, monthly peer-reviewed clinical medicine journal published by the Massachusetts Medical Society as part of the NEJM Group family of publications. Launched in January 2022 under founding Editor-in-Chief Jeffrey M. Drazen, M.D., and currently led by Editor-in-Chief Chana A. Sacks, M.D., M.P.H., the journal evaluates clinical trial design, challenges accepted clinical dogma, and advances biostatistical literacy across the international medical research community.

This page describes academic publishing standards and journal submission workflows; it is not clinical advice.

What it is

NEJM Evidence occupies a distinct position within biomedical publishing. While its flagship sibling, The New England Journal of Medicine (NEJM), focuses on landmark, practice-changing clinical investigations, NEJM Evidence examines the evidentiary foundation of clinical practice. The journal concentrates on the critical anatomy of clinical trials—evaluating trial endpoints, methodological design choices, protocol execution, statistical analysis assumptions, and areas where standard clinical interventions lack empirical backing.

The journal launched in January 2022 to address an expanding need in clinical science: the proliferation of clinical trials requiring nuanced methodological appraisal. Medical decision-makers frequently confront therapeutic choices informed by underpowered studies, surrogate markers, or unverified clinical conventions. By opening the methodology and statistical rationale behind clinical trials, NEJM Evidence provides a dedicated venue for rigorous randomized controlled trials, negative or neutral findings that contradict established dogma, early-phase investigations, and methodological critique.

From an organizational standpoint, NEJM Evidence is published by the Massachusetts Medical Society through the NEJM Group. Founding Editor-in-Chief Jeffrey M. Drazen, M.D., former Editor-in-Chief of NEJM, inaugurated the journal before transitioning to Editor-at-Large. In March 2024, Chana A. Sacks, M.D., M.P.H., an assistant professor of medicine at Harvard Medical School and Massachusetts General Hospital physician who served as Executive Editor since inception, was appointed Editor-in-Chief alongside Executive Editor C. Corey Hardin, M.D., Ph.D. The journal maintains the rigorous peer review and editorial integrity associated with the NEJM lineage.

Beyond traditional research communication, NEJM Evidence incorporates specialized educational initiatives designed to demystify biostatistical concepts for practicing clinicians. Through regular features that deconstruct statistical methodologies and critique trial designs, the journal cultivates critical appraisal skills among researchers, peer reviewers, and healthcare providers worldwide.

Who runs it and what it covers

NEJM Evidence is operated by the NEJM Group, the publishing division of the Massachusetts Medical Society located in Waltham and Boston, Massachusetts. The publication operates as an electronic-only monthly journal, identified in bibliographic records by Electronic ISSN 2766-5526, Linking ISSN 2766-5526, and National Library of Medicine identifier NLM ID 9918317485806676. Articles are indexed in MEDLINE, PubMed, the NLM Catalog, Clarivate’s Emerging Sources Citation Index (ESCI) within the Web of Science Core Collection, and Elsevier’s Scopus database.

The scope of NEJM Evidence encompasses primary clinical research, trial methodology, and evidence synthesis across clinical specialties, including cardiovascular medicine, oncology, infectious disease, critical care, endocrinology, pediatrics, and neurology. In particular, the editorial team prioritizes studies that challenge current clinical practices, comparative effectiveness research, pragmatic trials, decentralized study architectures, and investigations highlighting methodological trade-offs.

To serve these objectives, NEJM Evidence features a defined roster of article formats, each structured to address specific communication needs within the research ecosystem:

  • Original Articles: Rigorous reports of primary clinical research, including randomized clinical trials, observational cohorts, first-in-human studies, and formal meta-analyses. Original Articles require exhaustive documentation of study design and analytical plans.
  • Reviews: Comprehensive, evidence-based syntheses of therapeutic areas or diagnostic dilemmas, emphasizing the quality, consistency, and limitations of underlying clinical trials rather than descriptive summaries.
  • Tomorrow’s Trial: A signature editorial format highlighting routine clinical practices that lack high-grade randomized trial support. These short pieces articulate existing evidentiary deficits and invite readers to submit formal clinical trial proposals designed to resolve the uncertainty.
  • Stats, STAT!: An educational multimedia feature pairing concise editorial reviews with brief, animated explanatory videos that unpack fundamental and advanced biostatistical principles, from multi-arm trial designs to adaptive randomizations.
  • Morning Report: Interactive clinical case presentations structured in a journal club format, walking readers through patient presentation, differential diagnosis, diagnostic evaluation, and evidence-based management decisions.
  • Patient Platform: First-person essays written by clinical trial participants, offering qualitative insights into the participant experience, informed consent, trial communication, and the practical burdens of clinical research.
  • Editorials: Expert commentaries invited by the editors to contextualize newly published Original Articles, evaluate methodological rigor, and outline clinical implications.

The following table outlines the formal manuscript limits and structural parameters across the journal’s primary article categories as specified in the official author guidelines:

Article Format Body Word Limit Abstract Limit Display Items (Tables and Figures) Reference Limit Primary Focus
Original Article 2,700 words 250 words (Structured) Up to 5 combined 40 references Primary randomized trials, observational cohorts, and trial evaluations
Review 3,000 words 250 words (Unstructured) Up to 4 combined 60 references Critical appraisal of evidence bases and therapeutic uncertainties
Tomorrow’s Trial 1,000 words None Up to 2 combined 15 references Critique of unsupported clinical dogma and trial design proposals
Stats, STAT! 1,200 words None Up to 2 display items 15 references Biostatistical explainers and trial methodology tutorials
Morning Report 1,500 words None Up to 3 combined 15 references Case-based diagnostic reasoning and evidence application
Patient Platform 1,200 words None Up to 1 figure 10 references Participant perspective on clinical research protocol participation

Manuscripts reporting randomized controlled trials must provide complete documentation, including the full original clinical study protocol, any protocol amendments, and the prospective statistical analysis plan (SAP), which are published in online supplementary appendices alongside accepted papers.

How to search or use it

Authors submitting research manuscripts to NEJM Evidence interact directly with the journal’s online peer review platform, powered by Clarivate’s ScholarOne Manuscripts system. Navigating the submission pipeline requires preparing both core manuscript documents and institutional compliance materials. The following 6-step walkthrough outlines the formal submission and navigation process through the official ScholarOne portal:

  1. Access the ScholarOne Submission Portal and Register Author Profile: Navigate to the official submission gateway at ScholarOne Manuscripts (mc.manuscriptcentral.com/nejmevidence). Authors authenticate using institutional credentials or an existing ScholarOne account. During profile setup, the corresponding author links their active ORCID identifier to ensure persistent author attribution and automated bibliographic synchronization.
  2. Select Manuscript Type and Input Metadata: From the Author Dashboard, click Submit a New Manuscript. Select the precise submission category (such as Original Article, Review, or Tomorrow’s Trial). Enter the full manuscript title, running title, unstructured or structured abstract (Background, Methods, Results, Conclusions), and indexing keywords. Confirm that the author list accurately reflects contributions in accordance with International Committee of Medical Journal Editors (ICMJE) criteria.
  3. Verify Prospective Clinical Trial Registration: For all clinical trials, authors must input the official clinical trial registry name and unique trial identifier (e.g., ClinicalTrials.gov NCT identifier or World Health Organization International Clinical Trials Registry Platform portal number). The registration must have occurred prior to the enrollment of the first patient; retrospective registrations are evaluated critically and will result in desk rejection unless extraordinary, documented circumstances apply.
  4. Upload Full Trial Protocol, Statistical Analysis Plan, and Data-Sharing Statement: Authors upload the primary manuscript document in Microsoft Word (.docx) format along with high-resolution figure files. Under the Supplementary File for Review designation, authors upload the complete clinical trial protocol, historical amendment logs, and the formal statistical analysis plan (SAP). Additionally, authors supply a mandatory data-sharing statement detailing what de-identified individual participant data (IPD) will be shared, under what access criteria, and through which repository. Compliance aligns with standard publisher data-sharing policies across medical research.
  5. Submit Conflict of Interest Disclosures and Funding Declarations: All listed authors must complete the ICMJE Disclosure of Potential Conflicts of Interest form. Within the submission interface, the submitting author must certify that financial support, grant numbers, commercial sponsorships, and study monitoring arrangements have been transparently documented in title page declarations.
  6. Track Peer Review Stages and Address Revisions: Once submitted, the manuscript undergoes initial editorial triage. Manuscripts advancing past screening are assigned to an Associate Editor and sent for external journal peer review by clinical subspecialists and statistical reviewers. Authors monitor status updates (such as Under Review, Awaiting Decision, and Revision Requested) via the ScholarOne dashboard. Revised manuscripts require a comprehensive point-by-point response to reviewer critiques alongside track-changes versions of the manuscript and statistical appendices.

For clinicians and institutional subscribers seeking published research, NEJM Evidence provides search filtering on its native platform (evidence.nejm.org). Users can query articles by clinical specialty, study design (e.g., randomized trial, meta-analysis, observational study), or article format. Subscribers can also access animated Stats, STAT! video modules and download slide presentations directly for academic journal clubs.

Strengths and limits

Evaluating NEJM Evidence requires understanding its specialized editorial mission, its institutional assets, and the practical constraints inherent in its publishing framework.

Editorial and Educational Strengths

  • Methodological Rigor and Statistical Transparency: Unlike general medical journals that compress trial methodology into brief online supplements, NEJM Evidence elevates study design, analytical assumptions, and protocol fidelity to primary editorial criteria. Editors scrutinize statistical power calculations, handling of missing data, multiplicity adjustments, and the choice between intent-to-treat vs. per-protocol analysis.
  • High-Impact Peer Review and Pedigree: Submissions receive the same level of rigorous peer review and statistical evaluation historically associated with the NEJM Group. Each accepted trial is appraised by both expert clinical peers and professional biostatisticians.
  • Innovative Educational Features: Signature departments like Tomorrow’s Trial and Stats, STAT! provide tangible utility for residency programs, fellowship curricula, and clinical epidemiology courses, turning primary research into active teaching tools.
  • Fast-Track Indexing and Strong Metrics: Following its 2022 launch, the journal achieved comprehensive indexing across MEDLINE, PubMed, and ESCI. In Clarivate’s Journal Citation Reports, it secured an inaugural Journal Impact Factor of 11.6, ranking in the Q1 quartile for General and Internal Medicine, complemented by a Scopus CiteScore of 11.7.

Publishing Limits and Operational Considerations

  • Subscription and Paywall Barriers: Operating under the NEJM Group subscription model, full article access requires an individual subscription or institutional site license. While select educational videos and public health items are freely available, readers at unfunded institutions face access barriers compared to gold open-access journals.
  • Selective Acceptance and Stringent Criteria: Because the journal maintains high evidentiary thresholds, the editorial rejection rate is substantial. Studies with incomplete prospective registration, undocumented protocol modifications, or inadequate statistical analysis plans face immediate rejection.
  • Digital-Only Publication Schedule: As an electronic-only publication, NEJM Evidence does not produce print editions. While this facilitates rapid dissemination of multimedia content, animated graphics, and extended supplementary data, it differs from the physical distribution model of the flagship NEJM.
  • Niche Methodological Positioning: While highly respected by trialists and methodologists, some authors seeking immediate general-audience visibility may still prioritize broad-spectrum clinical outlets before considering methodology-focused venues.

Alternatives

Authors selecting an outlet for clinical trials and evidence evaluations must consider several alternative journals. Depending on whether a study delivers landmark clinical trial findings, protocol blueprints, secondary evidence syntheses, or broad clinical epidemiology, different publishing venues offer distinct editorial profiles, access models, and review timelines.

The comparative table below examines primary alternatives to NEJM Evidence, evaluating publisher affiliation, core scope, access models, and editorial emphasis:

Journal Publisher Core Scope and Editorial Focus Trial Reporting Requirements Publishing and Access Model Target Metrics and Indexing
NEJM Evidence Massachusetts Medical Society (NEJM Group) Clinical trial design, methodology, evidentiary limits, and statistical literacy Mandatory prospective registration, full protocol, and statistical analysis plan Subscription with funder compliance pathways ESCI JIF 11.6 (Q1), Scopus CiteScore 11.7, PubMed/MEDLINE
The New England Journal of Medicine (NEJM) Massachusetts Medical Society (NEJM Group) Landmark, practice-changing randomized trials and major clinical reviews Exhaustive protocol and statistical appendices; highest tier evidentiary standard Subscription with hybrid funder open access options SCIE JIF 96.2, PubMed/MEDLINE, global top tier general medicine
The Lancet Elsevier High-impact global randomized trials, public health, and specialty medicine Full prospective trial registration, CONSORT compliance, and protocol review Subscription with hybrid Gold Open Access options SCIE JIF 98.4, PubMed/MEDLINE, global reach
JAMA Network Open American Medical Association (AMA) Broad-spectrum clinical trials, observational studies, and health policy ICMJE prospective trial registration and trial protocol submission Gold Open Access (author APC required) SCIE JIF 10.5, PubMed/MEDLINE, rapid online publication
BMJ Evidence-Based Medicine BMJ Publishing Group Evidence synthesis, systematic reviews, diagnostic accuracy, and critical appraisal PRISMA and Cochrane-aligned reporting for syntheses; trial appraisal Subscription with hybrid Gold Open Access options SCIE JIF 5.8, PubMed/MEDLINE, clinical epidemiology focus
Trials BioMed Central (Springer Nature) Trial methodology, study protocols, pilot studies, and completed trial reports Detailed study protocols, pilot analyses, and full SAP transparency Gold Open Access (author APC required) SCIE JIF 2.0, PubMed/MEDLINE, trial methodology specialization

When deciding between these venues, authors evaluate specific trade-offs:

NEJM Evidence vs. Flagship NEJM: Manuscripts demonstrating rigorous methodology that address focused clinical questions or produce neutral trial results without altering national practice guidelines are prime candidates for NEJM Evidence. In many cases, NEJM editors suggest transferring manuscripts to NEJM Evidence, preserving reviewer evaluations within the publishing group.

NEJM Evidence vs. JAMA Network Open: Authors with institutional or funder mandates requiring immediate Gold Open Access under a Creative Commons CC BY license may favor JAMA Network Open or other open-access titles, provided grant funding is available to cover the requisite Article Processing Charge. Conversely, authors seeking zero author-facing publication fees under traditional publishing routes frequently prefer NEJM Evidence.

NEJM Evidence vs. Trials: For investigators seeking to publish a stand-alone clinical trial protocol, pilot feasibility study, or purely technical randomization algorithm before data collection commences, Trials offers a dedicated protocol category. In contrast, NEJM Evidence focuses on completed clinical research, major meta-analyses, and overarching methodological critiques that directly inform clinical decision-making.

Understanding how the Journal Impact Factor is calculated helps investigators contextualize these citation distributions and balance journal prestige against turnaround velocity and open access requirements.

Frequently asked questions

What is the relationship between NEJM Evidence and The New England Journal of Medicine?

NEJM Evidence is an independent, peer-reviewed digital journal published by the Massachusetts Medical Society under the NEJM Group umbrella. While the flagship NEJM focuses on broad, practice-changing clinical investigations, NEJM Evidence specifically interrogates clinical trial design, trial methodology, and statistical decision-making, applying the same editorial standards to a specialized methodological scope.

Does NEJM Evidence charge authors an Article Processing Charge (APC)?

NEJM Evidence does not charge mandatory submission fees or standard author publication fees for manuscripts accepted through its traditional subscription publishing route. For authors subject to specific funder mandates requiring immediate open access under Creative Commons licensing, the NEJM Group provides compliant deposit and publishing arrangements.

What is NEJM Evidence’s Journal Impact Factor and indexing status?

NEJM Evidence is indexed in MEDLINE, PubMed, the NLM Catalog (NLM ID 9918317485806676, eISSN 2766-5526), Clarivate’s Emerging Sources Citation Index (ESCI), and Scopus. In Clarivate’s Journal Citation Reports, it received an inaugural Journal Impact Factor of 11.6, ranking in the Q1 quartile for Medicine, General and Internal, with a Scopus CiteScore of 11.7.

What are the primary manuscript word count and display item limits for Original Articles?

Original Articles submitted to NEJM Evidence are capped at 2,700 words for the main body text (excluding abstract, references, and table/figure legends). They require a structured abstract of up to 250 words, a maximum of 5 combined tables and figures, and up to 40 references. Extended data, protocols, and statistical analysis plans are accommodated in online supplementary appendices.

What is Tomorrow’s Trial in NEJM Evidence?

Tomorrow’s Trial is a signature feature of NEJM Evidence that publishes short, focused articles identifying widely adopted clinical practices that lack high-grade randomized trial evidence. The section highlights specific evidentiary gaps and invites clinician-readers to submit formal clinical trial designs to test and validate those practices.

What is Stats, STAT! and how does it function?

Stats, STAT! is an educational multimedia initiative published in NEJM Evidence that pairs concise editorial reviews with brief, animated videos. The feature breaks down complex biostatistical concepts—such as adaptive trial designs, Bayesian analyses, and multiplicity adjustments—to help clinical practitioners critically evaluate medical research.

Is prospective clinical trial registration mandatory for submission to NEJM Evidence?

Yes. In accordance with International Committee of Medical Journal Editors (ICMJE) guidelines, all clinical trials submitted to NEJM Evidence must be prospectively registered in a publicly accessible trial registry (such as ClinicalTrials.gov or a WHO ICTRP primary registry) before enrolling the first patient. Unregistered or retrospectively registered trials are subject to immediate rejection.

Sources

  • NEJM Group, Massachusetts Medical Society. “About NEJM Evidence.” https://evidence.nejm.org/about (accessed 2026-11-15).
  • NEJM Group, Massachusetts Medical Society. “NEJM Evidence Author Center and Submission Guidelines.” https://evidence.nejm.org/author-center (accessed 2026-11-15).
  • National Library of Medicine. “NEJM Evidence – NLM Catalog Record (NLM ID 9918317485806676, ISSN 2766-5526).” https://www.ncbi.nlm.nih.gov/nlmcatalog/9918317485806676 (accessed 2026-11-15).
  • Clarivate. “Journal Citation Reports: NEJM Evidence Emerging Sources Citation Index (ESCI) Profile and Journal Impact Factor.” https://mjl.clarivate.com/ (accessed 2026-11-15).
  • Elsevier. “Scopus Source Record: NEJM Evidence (CiteScore and SJR Metrics).” https://www.scopus.com/sourceid/21101138883 (accessed 2026-11-15).
  • International Committee of Medical Journal Editors. “Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals.” https://www.icmje.org/recommendations/ (accessed 2026-11-15).

Data: Clinical Trial and Evidence Journals Comparison

Comparative cross-sectional analysis of leading clinical trial and evidence-focused medical journals, evaluating methodology requirements, trial registration policies, open access models, and indexing based on official author guidelines and bibliographic catalog records.

Period covered: 2022/2026. Coverage: Global.

Clinical Trial and Evidence Journals Comparison
JournalPublisherClinical Trial FocusTrial Protocol and SAP PolicyProspective Registration MandatePublishing ModelPrimary Indexing and Metric
NEJM EvidenceMassachusetts Medical Society (NEJM Group)Clinical trial design, execution, evidentiary limits, and statistical literacyMandatory protocol and full statistical analysis plan at submissionMandatory ICMJE-compliant prospective registration prior to first patientSubscription with funder-compliant public access deposit pathwaysESCI JIF 11.6, Scopus CiteScore 11.7, PubMed/MEDLINE
The New England Journal of MedicineMassachusetts Medical Society (NEJM Group)Landmark practice-changing randomized controlled trials and clinical medicineMandatory protocol and statistical analysis plan for original researchMandatory ICMJE-compliant prospective registration prior to first patientSubscription with hybrid funder open access pathwaysSCIE JIF 96.2, PubMed/MEDLINE, global top-tier general medicine
The LancetElsevierGlobal health randomized trials and high-impact clinical interventionsMandatory protocol and statistical analysis plan submissionMandatory ICMJE-compliant prospective registration prior to first patientSubscription with hybrid Gold Open Access optionsSCIE JIF 98.4, PubMed/MEDLINE, global reach
JAMA Network OpenAmerican Medical Association (AMA)Broad clinical trials, observational cohorts, and health policyProtocol required for all randomized clinical trial submissionsMandatory ICMJE-compliant prospective registration prior to first patientGold Open Access with mandatory author processing chargeSCIE JIF 10.5, PubMed/MEDLINE, rapid digital dissemination
BMJ Evidence-Based MedicineBMJ Publishing GroupSecondary evidence synthesis, systematic reviews, and critical appraisalPRISMA protocols preferred for systematic reviews and meta-analysesStrongly recommended registration in PROSPERO or clinical registriesSubscription with hybrid Gold Open Access optionsSCIE JIF 5.8, PubMed/MEDLINE, clinical epidemiology focus
TrialsBioMed Central (Springer Nature)Clinical trial methodology, study protocols, and randomized controlled trial reportsFull study protocol and statistical analysis plan published in open access formatMandatory prospective trial registration prior to first patient enrollmentGold Open Access with mandatory author processing chargeSCIE JIF 2.0, PubMed/MEDLINE, trial methodology specialization

Sources

Compiled by CASRAI from the sources above. Free to reuse under CC BY 4.0 with attribution.

Follow CASRAI

Research-administration guidance, standards updates and independent tool reviews.

Ask CASRAI · free to try

Ask about NEJM Evidence: Journal Scope, Clinical Trial Standards, and Submission Guide

Ask your first 2 questions free below. Subscribers get 150 a day for $29 a month.

An AI assistant specialized in research administration. It cites the sources behind every answer, labels web answers and says when it can't answer.

Answers draw on CASRAI's guides and dictionary plus the federal and funder documents we index: Federal Register, Grants.gov, Regulations.gov and UKRI.

Works on this site and inside Claude, Cursor and the AI tools you already use.

Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays free to read, with no account and no card.

Referenced across the research world

University of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logoUniversity of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logo
  • University of Cambridge logo
  • Columbia University logo
  • Crossref logo
  • University of Edinburgh logo
  • Harvard University logo
  • University of Oxford logo
  • Princeton University logo
  • Stanford School of Medicine logo
  • University College London logo
  • ORCID logo

View CASRAI adoption →